January 11, 2021
Tapan M. Kadia, MD, discusses the treatment options for patients with newly diagnosed acute myeloid leukemia.
January 09, 2021
Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.
January 06, 2021
The FDA lifted the partial clinical hold that was placed on a phase 2 study of MT-401 as treatment of patients with post-transplant acute myeloid leukemia.
January 05, 2021
An Independent Data Monitoring Committee has recommended the pivotal phase 3 SIERRA study continue as planned to full enrollment of 150 patients based on the findings from a pre-planned ad hoc interim analysis of the study.
January 02, 2021
In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
December 25, 2020
Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
December 21, 2020
A review by an Independent Data Monitoring Committee determined that combination of gilteritinib plus azacitidine would not likely improve overall survival compared with azacitidine alone in patients newly diagnosed FLT3-positive acute myeloid leukemia who were ineligible for intensive induction chemotherapy, missing the primary end point of the phase 3 LACEWING clinical trial.
December 15, 2020
The FDA granted a Fast Track designation to devimistat for the treatment of patients with acute myeloid leukemia.
December 08, 2020
Treatment with higher doses of CPX-351 in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia was significantly associated with prolonged hematologic recovery times during induction cycles 1 and 2.
December 07, 2020
The most important factor associated with poor survival among patients below 60 years of age with acute myeloid leukemia was self-reported black race in a SEER analysis.